Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001)

Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to see if the study drug, QTX3034, either with or without cetuximab, is safe and effective for treating KRAS G12D mutated cancer. We are also trying to find the best dose of QTX3034 to use.

Who Can Participate?

Eligibility

Adults with solid tumors that:
  • Are locally advanced or metastatic
  • Contain a KRAS G12D mutation
  • Have worsened following at least 1 line of standard therapy
For more information about this study, please contact the study team at 919-668-1861.

What is Involved?

Description

If you choose to join this study, you will:
  • Take the study drug, QTX3034, by mouth twice every day
  • Depending on which group you are assigned to, you may also get IV infusions of cetuximab once every week
  • Have your tumor biopsied
  • Give blood and urine samples
  • Have regular CT or MRI scans

Study Details

Full Title

[QTX3034-001] A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation

Principal Investigator

John
Strickler

Protocol Number

PRO00114908

NCT ID

NCT06227377

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov